Here we describe the derivation of tumour-targeting attenuated S. typhimurium engineered to provide prolonged therapeutic RNAi of the oncogenic driver c-Myc in immunocompetent animal models of colorectal and breast cancer. The gene discussed is MYC; the disease is breast cancer.